RhumbLine Advisers
BOLT icon

RhumbLine Advisers’s Bolt Biotherapeutics BOLT Stock Holding History

RhumbLine Advisers’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,183
Closed -$65K – 3111
2022
Q1 		$65K Buy
1,183
+120
+11% +$8.08K ﹤0.01% 2952
2021
Q4 		$104K Sell
1,063
-10
-0.9% -$1.9K ﹤0.01% 2936
2021
Q3 		$271K Buy
1,073
+413
+63% +$117K ﹤0.01% 2805
2021
Q2 		$204K Buy
660
+121
+22% +$49.1K ﹤0.01% 2919
2021
Q1 		$355K Buy
+539
New +$351K ﹤0.01% 2638

Other funds holding BOLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

RhumbLine Advisers's BOLT Position: Q2 2022 in Review

RhumbLine Advisers sold out of Bolt Biotherapeutics (BOLT) in Q2 2022, closing a stake of 1,183 shares — an estimated $65K sold.

RhumbLine Advisers first reported a position in BOLT in Q1 2021 and held it in 5 quarters. The position peaked at $355K in Q1 2021. 61 funds tracked by Wall St. Rank hold BOLT as of Q2 2022.

  • RhumbLine Advisers reported no remaining Bolt Biotherapeutics position as of Q2 2022 after selling out during the quarter.
  • RhumbLine Advisers sold 1,183 Bolt Biotherapeutics shares in Q2 2022, an estimated $65K.
  • RhumbLine Advisers first reported a position in Bolt Biotherapeutics in Q1 2021 and held it in 5 quarters.
  • RhumbLine Advisers's Bolt Biotherapeutics position peaked at $355K in Q1 2021.
  • 61 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2022.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.